tamsulosin hydrochloride (TAM) and tolterodine tartrate (TTD) in pharmaceutical formulations. The
method effectively separates the drugs using an ODS column and gradient elution at a flow rate of
1.0 mL/min. Fluorescence detection was used to measure the relative fluorescence intensity (RFI) of
the analytes, with excitation and emission wavelengths set at 280 nm and 350 nm, respectively. The
retention times for TAM and TTD were determined to be 5.66 and 7.26 min, respectively. The method’s
accuracy and precision were validated according to ICH guidelines. Linear calibration curves were
obtained over the concentration ranges of 0.1–1.5 μg mL-1 for TAM and 1–15 μg mL-1 for TTD, with
correlation coefficients exceeding 0.9995. The calculated LOD values for TAM and TTD were 0.03 and
0.30 μg mL-1, respectively. The corresponding LOQ values were 0.10 and 0.92 μg mL-1, respectively.
The method’s applicability was demonstrated by analyzing pharmaceutical dosage forms and spiked
plasma and urine samples. The observed mean recoveries percent were 99.31-100.97% for TAM
and 100.56-101.79% for TTD in human plasma, while in human urine, they were 98.71-101.55% for
TAM and 99.53-101.84% for TTD. To evaluate the method’s greenness, GAPI and AGREE tools were
employed. The results indicated significant adherence to green chemistry principles.